Interleukin-10 Protects Schwann Cells against Advanced Glycation End Products-Induced Apoptosis via NF-κB Suppression

Abstract

Demyelination resulting from Schwann cell injury is a main pathological feature of diabetic neuropathy, and a key contributor to this process may be inflammation due to advanced glycation end products (AGEs). Therefore, protection by anti-inflammation agents is anticipated. In this study, we showed that interleukin-10 (IL-10), an anti-inflammatory cytokine, inhibits apoptosis of Schwann cells induced by AGEs in vitro. We isolated and cultured Schwann cells from rat sciatic nerves. As detected by flow cytometry, apoptosis of Schwann cells markedly increased following incubation with AGEs for 48 h. However, pretreatment with IL-10 inhibited AGE-induced apoptosis. The effect of IL-10 on NF-κB, which is a very important regulator of inflammation, was also evaluated, and results showed high levels of phospho-NF-κB and nuclear localization of NF-κB in cells incubated with AGEs but low levels of phospho-NF-κB and cytoplasmic localization in the cells incubated with IL-10, indicating the activation of NF-κB by AGEs and inhibition of NF-κB by IL-10. Moreover, incubating Schwann cells with an NF-κB inhibitor (caffeic acid phenethyl ester) for 30 min before adding AGEs mimicked IL-10, lowering the amount of reactive oxygen species and activity of caspase-3 and also decreasing apoptosis in Schwann cells. These results indicate that IL-10 may protect Schwann cells against AGE-induced apoptosis by attenuating oxidative stress via the inhibition of activation of NF-κB.

Key words

diabetic neuropathy - advanced glycation end products - schwann cell - apoptosis - IL-10

• References

• 1 Callaghan BC, Cheng HT, Stables CL. et al. Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol 2012; 11: 521-534
• 2 Magnani P, Thomas TP, Tennekoon G. et al. Regulation of glucose transport in cultured Schwann cells. J Peripher Nerv Syst 1998; 3: 28-36
• 3 Muona P, Sollberg S, Peltonen J. et al. Glucose transporters of rat peripheral nerve. Differential expression of GLUT1 gene by Schwann cells and perineural cells in vivo and in vitro. Diabetes 1992; 41: 1587-1596
• 4 Goncalves NP, Vaegter CB, Andersen H. et al. Schwann cell interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol 2017; 13: 135-147
• 5 Myers SF. Myelin-sheath abnormalities in the vestibular nerves of chronically diabetic rats. Otolaryngol Head Neck Surg 1998; 119: 432-438
• 6 Mizisin AP, Shelton GD, Wagner S. et al. Myelin splitting, Schwann cell injury and demyelination in feline diabetic neuropathy. Acta Neuropathol 1998; 95: 171-174
• 7 Padilla A, Descorbeth M, Almeyda AL. et al. Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res 2011; 1370: 64-79
• 8 Delaney CL, Russell JW, Cheng HL. et al. Insulin-like growth factor-I and over-expression of Bcl-xL prevent glucose-mediated apoptosis in Schwann cells. J Neuropathol Exp Neurol 2001; 60: 147-160
• 9 Eckersley L. Role of the Schwann cell in diabetic neuropathy. Int Rev Neurobiol 2002; 50: 293-321
• 10 Eckersley L, Ansselin AD, Tomlinson DR. Effects of experimental diabetes on axonal and Schwann cell changes in sciatic nerve isografts. Brain Res Mol Brain Res 2001; 92: 128-137
• 11 Niimi N, Yako H, Tsukamoto M. et al. Involvement of oxidative stress and impaired lysosomal degradation in amiodarone-induced schwannopathy. Eur J Neurosci 2016; 44: 1723-1733
• 12 Yan L, Xie M, Lu H et al. Anti-apoptotic effect of igf1 on schwann exposed to hyperglycemia is mediated by neuritin, a novel neurotrophic factor. Mol Neurobiol 2016
• 13 Yang X, Yao W, Shi H. et al. Paeoniflorin protects Schwann cells against high glucose induced oxidative injury by activating Nrf2/ARE pathway and inhibiting apoptosis. J Ethnopharmacol 2016; 185: 361-369
• 14 Yu Y, Ma X, Yang T. et al. Protective effect of hydrogen-rich medium against high glucose-induced apoptosis of Schwann cells in vitro. Mol Med Rep 2015; 12: 3986-3992
• 15 Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299
• 16 Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101
• 17 Yamagishi S, Fukami K, Ueda S. et al. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007; 8: 952-959
• 18 Schmidt AM, Stern D. Atherosclerosis and diabetes: The RAGE connection. Curr Atheroscler Rep 2000; 2: 430-436
• 19 Hosseini A, Abdollahi M. Diabetic neuropathy and oxidative stress: Therapeutic perspectives. Oxid Med Cell Longev 2013; 2013: 168039
• 20 Stitt AW, Curtis TM. Diabetes-related adduct formation and retinopathy. J Ocul Biol Dis Infor 2011; 4: 10-18
• 21 Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003; 419: 89-96
• 22 Neeper M, Schmidt AM, Brett J. et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004
• 23 Sekido H, Suzuki T, Jomori T. et al. Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. Biochem Biophys Res Commun 2004; 320: 241-248
• 24 Bucciarelli LG, Wendt T, Qu W. et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-2835
• 25 Wada R, Nishizawa Y, Yagihashi N. et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-520
• 26 Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 2005; 1043: 598-604
• 27 Sato K, Tatsunami R, Yama K. et al. Glycolaldehyde induces cytotoxicity and increases glutathione and multidrug-resistance-associated protein levels in Schwann cells. Biol Pharm Bull 2013; 36: 1111-1117
• 28 Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J 2018; 42: 188-195
• 29 Reynaert NL, Gopal P, Rutten EPA. et al. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. Int J Biochem Cell Biol 2016; 81: 403-418
• 30 Yamagishi SI, Matsui T, Ishibashi Y. et al. Phytochemicals against advanced glycation end products (AGEs) and the receptor system. Curr Pharm Des 2017; 23: 1135-1141
• 31 Hagiwara S, Sourris K, Ziemann M. et al. RAGE deletion confers renoprotection by reducing responsiveness to transforming growth factor-beta and increasing resistance to apoptosis. Diabetes 2018; 67: 960-973
• 32 Singh J, Chaudhari BP, Kakkar P. Baicalin and chrysin mixture imparts cyto-protection against methylglyoxal induced cytotoxicity and diabetic tubular injury by modulating RAGE, oxidative stress and inflammation. Environ Toxicol Pharmacol 2017; 50: 67-75
• 33 Matsui T, Nakamura N, Ojima A. et al. Sulforaphane reduces advanced glycation end products (AGEs)-induced inflammation in endothelial cells and rat aorta. Nutr Metab Cardiovasc Dis 2016; 26: 797-807
• 34 Figarola JL, Shanmugam N, Natarajan R. et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 2007; 56: 647-655
• 35 Zhu Y, Liu Z, Peng YP. et al. Interleukin-10 inhibits neuroinflammation-mediated apoptosis of ventral mesencephalic neurons via JAK-STAT3 pathway. Int Immunopharmacol 2017; 50: 353-360
• 36 Noto MJ, Becker KW, Boyd KL et al. RAGE-mediated suppression of interleukin-10 results in enhanced mortality in a murine model of acinetobacter baumannii sepsis. Infect Immun 2017; 85:
• 37 Koulis C, Watson AM, Gray SP. et al. Linking RAGE and nox in diabetic micro- and macrovascular complications. Diabetes Metab 2015; 41: 272-281
• 38 Papa CM, Cesnik AJ, Evans TC. et al. Electrochemical synthesis of binary and ternary niobium-containing oxide electrodes using the p-benzoquinone/hydroquinone redox couple. Langmuir 2015; 31: 9502-9510
• 39 Thakur V, Gonzalez M, Pennington K. et al. Viral vector mediated continuous expression of interleukin-10 in DRG alleviates pain in type 1 diabetic animals. Mol Cell Neurosci 2016; 72: 46-53
• 40 Duksal T, Tiftikcioglu BI, Bilgin S. et al. Role of inflammation in sensory neuropathy in prediabetes or diabetes. Acta Neurol Scand 2016; 133: 384-390
• 41 Dworacka M, Iskakova S, Krzyzagorska E. et al. Alpha-lipoic acid modifies circulating angiogenic factors in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2015; 107: 273-279
• 42 Kolla VK, Madhavi G, Pulla Reddy B. et al. Association of tumor necrosis factor alpha, interferon gamma and interleukin 10 gene polymorphisms with peripheral neuropathy in South Indian patients with type 2 diabetes. Cytokine 2009; 47: 173-177
• 43 Moustafa PE, Abdelkader NF, El Awdan SA. et al. Extracellular matrix remodeling and modulation of inflammation and oxidative stress by sulforaphane in experimental diabetic peripheral neuropathy. Inflammation 2018; 41: 1460-1476
• 44 Moustafa PE, Abdelkader NF, El Awdan SA. et al. Liraglutide ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling. J Neurochem 2018; 146: 173-185
• 45 Wu HY, Tang XQ, Mao XF. et al. Autocrine Interleukin-10 mediates glucagon-like peptide-1 receptor-induced spinal microglial beta-endorphin expression. J Neurosci 2017; 37: 11701-11714
• 46 Liu WH, Liu JJ, Wu J. et al. Retraction: Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One 2018; 13: e0194455
• 47 Balaji S, Wang X, King A. et al. Interleukin-10-mediated regenerative postnatal tissue repair is dependent on regulation of hyaluronan metabolism via fibroblast-specific STAT3 signaling. FASEB J 2017; 31: 868-881
• 48 Zhou J, Ling J, Song J. et al. Interleukin 10 protects primary melanocyte by activation of Stat-3 and PI3K/Akt/NF-kappaB signaling pathways. Cytokine 2016; 83: 275-281
• 49 Shi J, Li J, Guan H. et al. Anti-fibrotic actions of interleukin-10 against hypertrophic scarring by activation of PI3K/AKT and STAT3 signaling pathways in scar-forming fibroblasts. PLoS One 2014; 9: e98228
• 50 Toth C, Rong LL, Yang C. et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008; 57: 1002-1017
• 51 Bierhaus A, Schiekofer S, Schwaninger M. et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-2808
• 52 Patel S, Santani D. Role of NF-kappa B in the pathogenesis of diabetes and its associated complications. Pharmacol Rep 2009; 61: 595-603
• 53 Koushki D, Latifi S, Norouzi Javidan A. et al. Efficacy of some non-conventional herbal medications (sulforaphane, tanshinone IIA, and tetramethylpyrazine) in inducing neuroprotection in comparison with interleukin-10 after spinal cord injury: A meta-analysis. J Spinal Cord Med 2015; 38: 13-22